Another protein essential for the inhibition of p53 function is MDMX, a homologue of MDM2 that is also overexpressed in many tumor types, thus disruption of the three-protein complex—MDMX/MDM2/p53—offers another option for the pharmacological treatment of wild-type p53 tumors [187]. This evidence concerns the gene MDM2 and neoplasm.